Business ❯ Pharmaceuticals

Acquisitions

Drug Development Biotechnology Corporate Strategy Mergers and Acquisitions Merck Sanofi Novartis Eli Lilly Biopharmaceuticals Oncology

Jazz Pharmaceuticals to Buy Actio Biosciences for $820 Million

The deal strengthens Jazz’s rare-epilepsy pipeline by adding ABS-1230, an oral precision therapy now in a Phase Ib/IIa registrational trial.

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

Eli Lilly Agrees to Buy Psychedelic Biotech AtaiBeckley for $2.8 Billion

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

Moderna Signals Interest in Buying Biontech's German Plants

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

Lilly Agrees to Buy Three Vaccine Developers for Up to $3.8 Billion

Lilly Acquires Engage Biologics for Up to $202 Million

Zydus to Buy Assertio for $166.4 Million in All-Cash Deal

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Deutsche Bahn Sets May Tests for Italy’s Frecciarossa 1000 in Germany and Austria

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs